156 related articles for article (PubMed ID: 25026995)
1. Analyzing temozolomide medication errors: potentially fatal.
Letarte N; Gabay MP; Bressler LR; Long KE; Stachnik JM; Villano JL
J Neurooncol; 2014 Oct; 120(1):111-5. PubMed ID: 25026995
[TBL] [Abstract][Full Text] [Related]
2. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
Grossman SA; Ye X; Piantadosi S; Desideri S; Nabors LB; Rosenfeld M; Fisher J;
Clin Cancer Res; 2010 Apr; 16(8):2443-9. PubMed ID: 20371685
[TBL] [Abstract][Full Text] [Related]
3. Hematologic adverse events associated with temozolomide.
Villano JL; Letarte N; Yu JM; Abdur S; Bressler LR
Cancer Chemother Pharmacol; 2012 Jan; 69(1):107-13. PubMed ID: 21614470
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
5. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Weller M; Gorlia T; Cairncross JG; van den Bent MJ; Mason W; Belanger K; Brandes AA; Bogdahn U; Macdonald DR; Forsyth P; Rossetti AO; Lacombe D; Mirimanoff RO; Vecht CJ; Stupp R
Neurology; 2011 Sep; 77(12):1156-64. PubMed ID: 21880994
[TBL] [Abstract][Full Text] [Related]
6. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
7. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.
Lombardi G; Rumiato E; Bertorelle R; Saggioro D; Farina P; Della Puppa A; Zustovich F; Berti F; Sacchetto V; Marcato R; Amadori A; Zagonel V
Am J Clin Oncol; 2015 Oct; 38(5):514-9. PubMed ID: 24064758
[TBL] [Abstract][Full Text] [Related]
9. Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme.
Guckenberger M; Mayer M; Buttmann M; Vince GH; Sweeney RA; Flentje M
Strahlenther Onkol; 2011 Sep; 187(9):548-54. PubMed ID: 21858417
[TBL] [Abstract][Full Text] [Related]
10. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
Gerstein J; Franz K; Steinbach JP; Seifert V; Rödel C; Weiss C
Strahlenther Onkol; 2011 Nov; 187(11):722-8. PubMed ID: 22037649
[TBL] [Abstract][Full Text] [Related]
11. Time trends in glioblastoma multiforme survival: the role of temozolomide.
Dubrow R; Darefsky AS; Jacobs DI; Park LS; Rose MG; Laurans MS; King JT
Neuro Oncol; 2013 Dec; 15(12):1750-61. PubMed ID: 24046259
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
Yung WK; Albright RE; Olson J; Fredericks R; Fink K; Prados MD; Brada M; Spence A; Hohl RJ; Shapiro W; Glantz M; Greenberg H; Selker RG; Vick NA; Rampling R; Friedman H; Phillips P; Bruner J; Yue N; Osoba D; Zaknoen S; Levin VA
Br J Cancer; 2000 Sep; 83(5):588-93. PubMed ID: 10944597
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
15. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme.
Roldán Urgoiti GB; Singh AD; Easaw JC
J Neurooncol; 2012 May; 108(1):173-7. PubMed ID: 22382781
[TBL] [Abstract][Full Text] [Related]
16. Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: a retrospective study.
Sridhar T; Gore A; Boiangiu I; Machin D; Symonds RP
Clin Oncol (R Coll Radiol); 2009 Feb; 21(1):19-22. PubMed ID: 18838255
[TBL] [Abstract][Full Text] [Related]
17. Glioblastoma management in the temozolomide era: have we improved outcome?
Lwin Z; MacFadden D; Al-Zahrani A; Atenafu E; Miller BA; Sahgal A; Menard C; Laperriere N; Mason WP
J Neurooncol; 2013 Nov; 115(2):303-10. PubMed ID: 23979682
[TBL] [Abstract][Full Text] [Related]
18. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
[TBL] [Abstract][Full Text] [Related]
20. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A
Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
